Drug exposure in a metastatic human lung adenocarcinoma cell line gives rise to cells with differing adhesion, proliferation, and gene expression: Implications for cancer chemotherapy

HUILING LI1,2, JIANXING HE1,2, NANSHAN ZHONG1,2 and ROBERT M. HOFFMAN3,4

1Department of Respiratory, Hainan Branch of PLA Hospital, Sanya, Hainan 572000; 2Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China; 3Department of Surgery, University of California, San Diego, CA 92111; 4AntiCancer, Inc., San Diego, CA 92111, USA

Received April 10, 2014; Accepted January 22, 2015

DOI: 10.3892/mmr.2015.3837

Abstract. The Am1010 cell line was previously established from a metastatic deposit in an arm muscle from a patient with lung adenocarcinoma who had undergone four cycles of chemotherapy with cisplatin and taxol. Am1010 cells were labeled with red fluorescent protein or green fluorescent protein. A total of eight sublines were isolated following in vitro exposure to cisplatin or taxol. The sublines differed with regard to their adhesion and proliferation properties, with certain sublines exhibiting an increased proliferation rate and/or decreased surface adhesion. Gene expression assays demonstrated that tenascin C; cyclin D1; collagen, type 1, α2; integrin α1; related RAS viral (r-ras) oncogene homolog 2; platelet-derived growth factor C; and Src homolog 2 domain containing in the focal adhesion pathway, and intercellular adhesion molecule 1, F11 receptor, claudin 7 and cadherin 1 in the cell adhesion pathway, varied in expression among the sublines. The results of the present study suggested that drug exposure may alter the aggressiveness and metastatic potential of cancer cells, which has important implications for cancer chemotherapy.

Introduction

Lung cancer is the leading cause of mortality among all types of malignancy (1). Regardless of the treatment provided, the 5-year survival rate in lung cancer is <15%. The poor prognosis is predominantly attributed to the development of drug resistance (2). It is therefore important to identify the mechanisms underlying drug resistance in lung cancer.

Cancer stem cells (CSCs) exhibit increased drug resistance and tumorigenicity (3,4). Levina et al (1) suggested that CSCs may be enriched and subsequently isolated from cancer cell populations following drug treatment. The authors isolated what they termed drug-surviving cells (DSCs) from human cancer cell lines treated with cisplatin, doxorubicin or etoposide. The isolated DSCs were clonogenic, expressed CSC cell surface and embryonic stem cell markers, exhibited self-renewal and differentiation, and were tumorigenic and metastatic in severe combined immunodeficiency mice. It was concluded that the DSCs were CSCs and that enrichment of CSCs following drug treatment in vitro may result in a similar selection of drug-resistant CSCs in patients during chemotherapy (1).

Our group previously established the cell line Am1010 (5) directly from a lung cancer patient who was treated with chemotherapy but developed multidrug resistance. In the present study, the establishment of eight sublines of DSCs from Am1010, labeled with red fluorescent protein (RFP) or green fluorescent protein (GFP), by long-term exposure to cisplatin or taxol is described. Cell proliferation and gene expression were then determined, in order to define the differences between the sublines.

Materials and methods

Ethics statement. All experimentation presented in the current study has been approved by the local institutional review board. The tumor sample was obtained from the Department of Thoracic Surgery at the 1st Affiliated Hospital of Guangzhou Medical College with the approval of the local ethical committee. Written informed consent was obtained from the patient.

RFP or GFP expression in Am1010 cells. The RFP (DsRed-2) gene (Clontech Laboratories, Mountain View, CA, USA) was
inserted in the retroviral-based mammalian expression vector, pLNCX (Clontech Laboratories), to form the pLNCX DsRed-2 vector. The EGFP gene (Clontech Laboratories) was inserted into the retroviral-based mammalian expression vector, pLEIN, to form the pLEIN EGFP vector. Transfection of pLNCX DsRed-2 or pLEIN GFP into PT67 packaging cells produced retroviral supernatants containing the DSRed-2 or EGFP gene. Briefly, PT67 cells were grown as monolayers in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS; Gemini Biological Products, Calabasas, CA, USA). Exponentially growing cells in 10-cm dishes were transfected with 10 µg of the expression vector using Lipofectamine® and Plus reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Transfected cells were replated 48 h after transfection and 100 µg/ml G418 was added. After two days, the quantity of G418 was increased to 200 µg/ml. During the drug selection period, surviving colonies were visualized under fluorescence microscopy and RFP-positive and GFP-positive colonies were isolated (6).

For RFP or GFP gene transduction, cells were incubated at 20% confluence with a 1:1 precipitated mixture of retrovirus-containing supernatants of PT67 cells and RPMI 1640 or other culture medium (Invitrogen Life Technologies) containing 10% FBS (Gemini Biological Products) for 72 h. Cells were replenished with fresh medium at this time. Cancer cells were harvested with trypsin/EDTA and subcultured at a ratio of 1:15 into selective medium, which contained 50 µg/ml G418. In order to select brightly fluorescent cells, the concentration of G418 was increased to 800 µg/ml in a stepwise manner. The clones of cancer cells expressing RFP or GFP were isolated using cloning cylinders (Bel-Art Products, Inc., Princeton, NJ, USA) by trypsin/EDTA and amplified and transferred by conventional culture methods in the absence of the selective agent (6).

Establishment of DSC sublines. Once Am1010 cells (5) had grown to 80% confluence, cisplatin (1 µM) was added to the medium for 1 month. Suspended cells appeared following drug exposure and were transferred to a new culture dish. Am1010 cells were also exposed to taxol (0.1 µM) in a procedure similar to that used for cisplatin. Am1010-cis-suspension-GFP, Am1010-cis-adhesion-GFP, Am1010-tax-suspension-GFP, Am1010-tax-adhesion-GFP, Am1010-cis-suspension-RFP, Am1010-cis-adhesion-RFP, Am1010-tax-suspension-RFP and Am1010-tax-adhesion-RFP cells were isolated by culture with cisplatin or taxol. When the DSC sublines were passaged, the suspended or attached status of the subline was maintained for 30-100 h. After this time period, the suspended cells attached and proliferated. The cells were subsequently cultured as normal cells, and their gene expression of CCND1, TNC, COL1A2, ITGA1, RRAS2, PDGFC, SHC1, ICAM1, CLDN7, F11R and CDH1 was assayed every three months, in order to observe their stability. Unstable cells were discarded.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The expression of tenascin C (TNC); cyclin D1 (CCND1); collagen, type I, α2 (COL1A2); integrin α1 (ITGA1); related RAS viral (r-ras) oncogene homolog 2 (RRAS2); platelet-derived growth factor C (PDGFC); Src homolog 2 domain containing (SHC1); intercellular adhesion molecule 1 (ICAM1); F11 receptor (F11R); claudin 7 (CLDN7); and cadherin 1 (CDH1) was analyzed by SYBR Green qPCR. Total RNA was isolated from cultured cells, omental tissues and oral mucosal tissues using the TRIzol® method (Invitrogen Life Technologies). The total quantity of RNA was determined using a Nanodrop spectrophotometer (ND1000; NanoDrop Technologies, Wilmington, DE, USA). The purity was assessed using denaturing agarose gel electrophoresis. cDNA synthesis was conducted with 1 µg of RNA using the High Capacity cDNA Reverse Transcription kit (Invitrogen Life Technologies). RT-qPCR was performed using an ABI Prism 7900HT system (Applied Biosystems, Foster City, CA, USA). RT-qPCR reactions were conducted using 26 Power SYBR Green PCR master mixes (Applied Biosystems) according to the manufacturer's instructions. For PCR amplification, an initial step at 50°C for 2 min was performed, followed by a denaturation step at 95°C for 15 min. Subsequently, 45 cycles of a denaturation step (95°C for 15 sec) and an annealing and extension step (60°C for 60 sec) were performed. PCR reactions were performed in triplicate for each sample. A dissociation reaction was also conducted for each primer in order to assess its specificity. The relative quantification (ΔΔCT method), which describes the change in expression of the target gene in a test sample relative to that in a calibrator sample, was used to analyze the data. Data were analyzed using the 7900HT sequence detector system software version 2.2.1 (Applied Biosystems). Results were expressed relative to the expression levels of internal reference genes (β-actin and GAPDH). Details of the primers used for specific genes are presented in Table I.

Cell proliferation measurements. Aliquots (100 µl) of exponentially growing cell suspensions (5x10⁴ cells/ml) were seeded in 96-well microtiter plates and incubated for 24 h. At 0, 24, 48 and 96 h, 20 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (5 mg/ml in phosphate-buffered saline) was added to each well and the plates were incubated at 37°C for an additional 3 h. Following centrifugation of the plates at 800 x g for 5 min, the medium was aspirated from each well as fully as possible and 200 µl of dimethyl sulfoxide was added to each well to dissolve the formazan crystals. The optical density was measured at 490 nm using the Delta-soft ELISA analysis software interfaced to a Bio-Tek microplate reader (EL-340; Biometallics, Inc., Princeton, NJ, USA).

Statistical analysis. Differences in proliferation between different cell lines were analyzed using Student's t-test. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Labeling of Am1010 sublines with GFP and RFP. Am1010 cells were stably labeled with GFP or RFP. Fig. 1 shows Am1010-GFP and Am1010-RFP cells. GFP and RFP expression did not alter the proliferation rate of the cells (data not shown).
DSC sublines of Am1010-GFP or Am1010-RFP had differing adhesion properties. Exposure of Am1010-GFP or Am1010-RFP cells to cisplatin or taxol, enabled the isolation of suspended or attached sublines. The following sublines were selected: Am1010-cis-suspension-GFP, Am1010-cis-adhesion-GFP, Am1010-cis-suspension-RFP, Am1010-cis-adhesion-RFP (Fig. 2), Am1010-tax-suspension-GFP, Am1010-tax-adhesion-GFP, Am1010-tax-suspension-RFP and Am1010-tax-adhesion-RFP (Fig. 3). When the DSC sublines were passaged, the suspension or attached status of the subline was maintained for 30-100 h. After this time period, the suspended cells attached and proliferated.

Gene expression of TNC, CCND1, COL1A2, ITGA1, RRAS2, PDGFC, SHC1, ICAM1, F11R, CLDN7 and CDH1 in the DSC sublines Am1010-GFP and Am1010-RFP. Am1010-cis-adhesion and Am1010-cis-suspension cells exhibited the same trend for the expression of the eleven genes measured. Expression of TNC, CCND1, COL1A2, ITGA1, RRAS2, SHC1 and ICAM1 was upregulated and that of F11R, CLDN7 and CDH1 expression was downregulated (all P<0.01), as compared with the Am1010 cells which have a basic value of 1 in Table II and Fig. 4, and the Am1010-tax-adhesion and Am1010-tax-suspension cells (all P<0.01). PDGFC expression exhibited little variation, as compared with the Am1010-tax-adhesion and Am1010-tax-suspension cells (P>0.05). Am1010-cis-adhesion cells revealed a greater degree of upregulation of gene expression than Am1010-cis-suspension cells. By contrast, Am1010-cis-suspension cells demonstrated a greater degree of downregulation of gene expression than Am1010-cis-adhesion cells.

All eleven genes exhibited little variation of expression in Am1010-tax-adhesion cells (P>0.05). By contrast, the expression of almost all genes, with the exception of TNC, which exhibited little variation, was downregulated in Am1010-tax-suspension cells (P<0.05; Table II and Fig. 4).

Table I. Gene expression analysis.

| Gene   | GB accession | Primer sequence 5’→3’ | Amplificon size (bp) |
|--------|--------------|-----------------------|----------------------|
| CCND1  | NM_053056    | Forward AGAACACGGGCTCACGCTTAC \n Reverse CCCAGACCCCTCAGACTTGC | 204 |
| TNC    | NM_002160    | Forward GAGATGCCAACAGACTCGTACA \n Reverse GTTGACACGGTGACAGTCTCTT | 182 |
| COL1A2 | NM_000089    | Forward CTACCCAACCTGCTCATG \n Reverse GTCTTTTCCATCATTGGCTAC | 229 |
| ITGA1  | NM_181501    | Forward TGCCCTCGAATGAAATACGA \n Reverse TTTTTGGGTCACATACTGGA | 109 |
| RRAS2  | NM_012250    | Forward GTTGAGAAGTTTTTACCTTCTG \n Reverse AGTTATTGAGTCTGCTACTG | 116 |
| PDGFC  | NM_016205    | Forward GTCTTTGGTACAGGCTT | 126 |
| SHC1   | NM_003029    | Forward CTATGACTCTAAGCAGCAGT | 183 |
| ICAM1  | NM_000201    | Forward GACCAACCACTGATGATA \n Reverse AGTCTTTGTGCCCGATAGA | 266 |
| CLDN7  | NM_001307    | Forward ATGTATAGCCTCTGTTGGTGG \n Reverse TCAGTTGGGTGCTAAGTTTC | 215 |
| F11R   | NM_016946    | Forward TCACTTGGTAAGCGTAGT \n Reverse CTAACCTCCTTCTCCACTA | 110 |
| CDH1   | NM_004360    | Forward GAGATTGATTGATGGTCGTC \n Reverse GGGATCTCGGCTTTTTGAGTA | 114 |
| GAPDH  | NM_002046    | Forward TGTTGCCATCAATAGCAACCTTT \n Reverse CTCCAGCAGTACTCACGGC | 202 |
| β-actin| NM_001101    | Forward CATGTACGTTGCTATCCAGCAGCAGT \n Reverse CTTCCTTAATGTCACGCCGACGAT | 250 |

CCND1, cyclin D1; TNC, tenascin C; COL1A2, collagen, type 1, α2; ITGA1, integrin α1; RRAS2, related RAS viral (r-ras) oncogene homolog 2; PDGFC, platelet-derived growth factor C; SHC1, Src homolog 2 domain containing; ICAM1, intercellular adhesion molecule 1; CLDN7, claudin 7; F11R, F11 receptor; CDH1, cadherin 1.
Differential cell proliferation rates in DSC sublines derived from Am1010-GFP and Am1010-RFP cells. The cell proliferation rate differed among the DSC sublines derived from Am1010-GFP and Am1010-RFP cells (P>0.05; Fig. 5). Am1010-cis-suspension-GFP cells and Am1010-cis-suspension-RFP cells were thus termed Am1010-cis-suspension cells. Am1010-cis-adhesion-GFP cells and Am1010-cis-adhesion-RFP cells were termed Am1010-cis-adhesion cells. Am1010-tax-suspension-GFP cells and Am1010-tax-suspension-RFP cells were termed Am1010-tax-suspension cells. Am1010-tax-adhesion-GFP cells and Am1010-tax-adhesion-RFP cells were termed Am1010-tax-adhesion cells. Am1010-cis-adhesion cells and Am1010-tax-adhesion cells had the highest and lowest proliferation rates, respectively (P<0.01).

Discussion

The present study describes the establishment of eight DSC sublines expressing either GFP or RFP, derived by drug exposure from the Am1010 cell line (5), which was established from a metastasis resected from a patient with lung cancer. These cell lines demonstrated in vitro multidrug resistance to cisplatin and taxol. Exposure of Am1010 cells in vitro to...
cisplatin or taxol resulted in sublines with varied proliferation and ability to attach to a cell culture dish.

The variability in the ability to attach to a cell culture dish indicated that the expression of certain genes associated with the adhesion pathway of Am1010 cells may vary following exposure to chemotherapy. In our previous study, eleven adhesion pathway genes, TNC, CCND1, COL1A2, ITGA1, RRAS2, PDGFC, SHC1, ICAM1, F11R, CLDN7 and CDH1...
were observed to be differentially expressed in a microarray analysis comparing expression in Am1010 cells with that in P0318 cells (5). In contrast to Am1010 cells, P0318 is a non-drug-surviving cell line. The patient from whom this cell line was obtained had not undergone chemotherapy and exhibited the same pathology as that of the donor of the Am1010 cell, with the exception of the presence of metastases (5). The differential expression of these genes in the two cell lines may be associated with their differing metastatic ability. TNC, CCND1, COL1A2, ITGA1, RRAS2, PDGFC and SHC1 are genes involved in the focal adhesion pathway and ICAM1, Src homolog 2 domain containing; ICAM1, intercellular adhesion molecule 1; CLDN7, claudin 7; F11R, F11 receptor; CDH1, cadherin 1.

Following cisplatin exposure, all cells exhibited a similar expression pattern for each of the eleven genes. TNC, CCND1, COL1A2, ITGA1, RRAS2, SHC1 and ICAM1 expression was upregulated and F11R, CLDN7 and CDH1 expression was downregulated. PDGFC expression exhibited little variation. Gene expression was more markedly upregulated in cells with improved attachment and more distinctly downregulated in cells with poorer attachment. Following taxol exposure, all eleven genes exhibited little change in expression in cells with improved attachment. By contrast, almost all of the evaluated genes were downregulated in cells that attached poorly, with the exception of TNC, which exhibited little change in expression. The differences in the adhesion properties of the sublines suggest that drug exposure may alter the aggressiveness and metastatic potential of cancer cells, which has important implications for cancer chemotherapy.

Cell proliferation assays indicated very different growth rates among the DSC sublines derived from Am1010-GFP cells or Am1010-RFP cells. Am1010-cis-adhesion-GFP cells grew at the fastest rate. Thus, drug resistance may led to an acceleration of the growth of cancer cells. Enhanced proliferation may make a tumor more aggressive. The results of the present study suggested that chemotherapy in patients with lung cancer may give rise to DSCs with altered proliferation and metastasis. Levina et al (1) suggested that CSCs may be enriched and subsequently isolated from cancer cell populations following drug exposure. The authors isolated DSCs from human cancer cell lines treated with cisplatin, doxorubicin or etoposide, and concluded that the DSCs were CSCs. Levina et al (1) stated that enrichment of CSCs following drug treatment in vitro suggests that a similar positive selection of drug-resistant CSCs may occur in patients during chemotherapy.

Studies by these group have demonstrated that drug exposure of cancer cells may result in DSCs, which vary significantly in proliferation, adhesion and gene expression (1,7). The present data suggested that drug exposure in cancer cells may generate highly aggressive variants. These results have important implications for the chemotherapy of lung cancer.

### Table II. Relative gene expression changes in different cell sublines.

|                | Am1010-cis-adhesion | Am1010-cis-suspension | Am1010-tax-adhesion | Am1010-tax-suspension |
|----------------|---------------------|-----------------------|---------------------|-----------------------|
| 2^ΔΔCT CCND1   | 1.92                | 1.34                  | 1.53                | 0.88                  |
| TNC            | 9.99                | 4.53                  | 1.11                | 1.25                  |
| COL1A2         | 2.55                | 1.01                  | 1.00                | 0.51                  |
| ITGA1          | 3.06                | 1.78                  | 0.70                | 0.48                  |
| RRAS2          | 1.50                | 1.31                  | 0.85                | 0.75                  |
| PDGFC          | 1.11                | 0.81                  | 0.66                | 0.47                  |
| SHC1           | 2.29                | 1.54                  | 0.94                | 0.57                  |
| ICAM1          | 2.54                | 1.33                  | 1.01                | 0.30                  |
| CLDN7          | 0.52                | 0.38                  | 0.71                | 0.31                  |
| F11R           | 0.31                | 0.11                  | 0.83                | 0.31                  |
| CDH1           | 0.21                | 0.19                  | 0.93                | 0.34                  |

CCND1, cyclin D1; TNC, tenasin C; COL1A2, collagen, type 1, α2; ITGA1, integrin α1; RRAS2, related RAS viral (r-ras) oncogen homolog 2; PDGFC, platelet-derived growth factor C; SHC1, Src homolog 2 domain containing; ICAM1, intercellular adhesion molecule 1; CLDN7, claudin 7; F11R, F11 receptor; CDH1, cadherin 1.
Acknowledgements

The present study was supported by the China Natural Science Foundation (grant no. 8100951), China Natural Postdoctoral Foundation (grant no. 20080440742), Government Technology Agency Foundation of Guangdong Province, China (grant no. 2007B031515017), Guangzhou City, China (grant nos. 2007Z1-E0111 and 2060402), and the Doctor Start Foundation of Guangzhou Medical College.

References

1. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.

2. Nadkar A, Pungaliya C, Drake K, Zajac E, Singhal SS and Awasthi S: Therapeutic resistance in lung cancer. Expert Opin Drug Metab Toxicol 2: 753-777, 2006.

3. Peacock CD and Watkins DN: Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26: 2883-2889, 2008.

4. Tysnes BB and Bjerkvig R: Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta 1775: 283-297, 2007.

5. Li HL, Xie SM, Zhang L, et al: Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol and gefitinib. Acta Pharmacol Sin 31: 601-608, 2010.

6. Hoffman RM and Yang M: Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc 1: 928-935, 2006.

7. Alamgeer M, Peacock CD, Matsui W, Ganju V and Watkins DN: Cancer stem cells in lung cancer: evidence and controversies. Respirology 18: 757-764, 2013.